FAQ: Lantern Pharma's Strategic Appointment to Enhance AI-Driven Oncology Research

Who has Lantern Pharma appointed to its Board of Directors?

Lantern Pharma has appointed Dr. Lee T. Schalop, co-founder and former CEO of Oncoceutics Inc., to its Board of Directors, bringing over 20 years of experience in biotechnology leadership and financial markets.

What expertise does Dr. Schalop bring to Lantern Pharma?

Dr. Schalop brings expertise in neurooncology and strategic transactions, with a track record in developing targeted therapies for solid tumors, including HK327M-mutant gliomas, aligning with Lantern’s AI-powered drug development platform.

Why is Dr. Schalop’s appointment significant for Lantern Pharma?

His appointment is significant because his expertise in strategic transactions and neurooncology is expected to accelerate Lantern’s precision oncology programs, particularly in CNS cancer, enhancing the company’s ability to deliver novel therapies.

What is Lantern Pharma’s focus?

Lantern Pharma focuses on transforming the cost, pace, and timeline of oncology drug discovery and development using its proprietary AI and machine learning platform, RADR(R), to accelerate the development of therapies for various cancer indications.

How does Lantern Pharma’s AI platform contribute to drug development?

The RADR(R) platform leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to solve real-world problems in oncology drug development, significantly reducing the time and cost of bringing new therapies to clinical trials.

What are the achievements of Lantern Pharma’s drug development programs?

Lantern’s drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program, showcasing the efficiency of its AI-driven approach.

Where can I find more information about Lantern Pharma’s latest news and updates?

The latest news and updates relating to Lantern Pharma (LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN.

What is the significance of Lantern Pharma’s subsidiary, Starlight Therapeutics?

Starlight Therapeutics, a subsidiary of Lantern Pharma, focuses on the CNS cancer pipeline, benefiting from Dr. Schalop’s expertise in neurooncology to accelerate the development of targeted therapies for central nervous system cancers.